UCB SA (ENXTBR:UCB) signed a definitive agreement to acquire Neurona Therapeutics, Inc. for $1.2 billion on April 17, 2026. A cash consideration of $650 million will be paid by UCB SA. UCB SA will pay an earnout payment of $500 million cash. As part of consideration, $1.15 billion is paid towards common equity of Neurona Therapeutics, Inc.

The transaction is subject to subject to antitrust regulations. The expected completion of the transaction in the end of Q2 2026.

Bank of America Corporation acted as financial advisor for UCB SA. Covington & Burling LLP acted as legal advisor for UCB SA. Centerview Partners LLC acted as financial advisor for Neurona Therapeutics, Inc. Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor for Neurona Therapeutics, Inc.